Influenza: Diagnosis, Antiviral Therapy, Hospital Management, and Vaccination
Seasonal influenza causes 290,000–650,000 respiratory deaths globally per year. RT-PCR has displaced rapid antigen testing for diagnosis; oseltamivir and baloxavir are the antiviral mainstays; secondary bacterial pneumonia (Streptococcus pneumoniae, Staphylococcus aureus including MRSA) is the leading cause of mortality. Annual vaccination, post-exposure prophylaxis, and timely antiviral initiation define modern management. IDSA 2018, CDC 2024 framework.
Executive Summary
Influenza is an acute respiratory illness caused by influenza A and B viruses (and rarely C). Influenza A is further classified by hemagglutinin (H1–H18) and neuraminidase (N1–N11) surface glycoproteins; H1N1 and H3N2 are the dominant human seasonal subtypes. Annual epidemics produce an estimated 5 million severe cases and 290,000–650,000 respiratory deaths globally; risk concentrates in adults ≥65 years, pregnant women, immunocompromised hosts, those with chronic cardiopulmonary disease, and morbid obesity. Diagnosis relies on RT-PCR (sensitivity 95–100%, specificity 99–100%) — rapid influenza diagnostic tests (RIDTs) have sensitivity only 50–70% and a negative test does not rule out influenza when prevalence is high. Treatment with neuraminidase inhibitors — oseltamivir 75 mg PO BID × 5 days — is most effective when started within 48 hours of symptom onset (reduces illness duration by ≈1 day, hospitalizations, and mortality in high-risk patients) but should be given to hospitalized patients regardless of duration. The polymerase acidic endonuclease inhibitor baloxavir marboxil 40 mg PO once (40 mg if 40–80 kg, 80 mg if ≥80 kg) is approved as single-dose alternative for outpatients but has higher rates of treatment-emergent resistance (PA/I38T mutation). Hospital admission is warranted for hypoxia, respiratory failure, sepsis physiology, exacerbation of underlying chronic disease, or social inability to take oral therapy. Secondary bacterial pneumonia is the leading cause of influenza mortality — Streptococcus pneumoniae, Staphylococcus aureus (including MRSA), and group A Streptococcus account for most cases; empiric coverage with ceftriaxone 1–2 g IV daily + vancomycin (AUC-guided) is recommended when bacterial superinfection is suspected. Influenza myocarditis, encephalopathy, ARDS, and rhabdomyolysis are recognized complications. Annual vaccination — quadrivalent inactivated (IIV4), recombinant (RIV4), live attenuated (LAIV4 for healthy 2–49 years), or high-dose IIV-HD/adjuvanted aIIV4 for ≥65 years — is the cornerstone of prevention; post-exposure prophylaxis with oseltamivir 75 mg PO daily × 7 days for high-risk household contacts when initiated within 48 hours of exposure.
S1. Virology, Epidemiology, and Clinical Spectrum
Influenza viruses belong to the Orthomyxoviridae family — segmented negative-sense RNA genomes encoding 10–14 proteins. Influenza A and B cause the bulk of human disease; influenza C causes mild upper respiratory illness in children. Influenza A is uniquely capable of major antigenic shift through reassortment between human, swine, and avian strains, generating pandemic potential (1918 H1N1, 1957 H2N2, 1968 H3N2, 2009 H1N1pdm09). Antigenic drift — accumulating point mutations in HA and NA — drives annual seasonal epidemics and necessitates yearly vaccine reformulation.
Transmission and Incubation
Transmission occurs via respiratory droplets, aerosols (during procedures and crowded environments), and fomites. Incubation is 1–4 days (median 2). Viral shedding begins 24 hours before symptom onset, peaks at days 2–3, and continues for 5–10 days in immunocompetent adults; immunocompromised patients may shed for weeks. The reproduction number (R0) for seasonal influenza is 1.2–1.4.
Clinical Presentation
Classic influenza presents abruptly with fever (38–40°C), myalgia, headache, malaise, dry cough, sore throat, and rhinorrhea. Children often have higher fevers, GI symptoms (vomiting, diarrhea), and febrile seizures. Older adults may have atypical presentations — minimal fever, confusion, fall, or anorexia. Symptoms last 3–7 days; cough and malaise can persist 1–2 weeks. Asymptomatic infection occurs in 5–25%.
High-Risk Populations
| Risk Category | Examples |
|---|---|
| Age | ≥65 years; children <5 years (especially <2) |
| Pregnancy | Pregnant or up to 2 weeks postpartum |
| Chronic medical conditions | Asthma, COPD, heart disease, diabetes, CKD, cirrhosis, neurologic/neuromuscular disease |
| Immunocompromise | Solid organ or HSCT recipients, HIV with CD4 <200, biologic or chemotherapy, congenital immunodeficiency |
| Other | BMI ≥40, residents of long-term care facilities, American Indian/Alaska Native populations |
The pathogenesis of influenza balances viral replication kinetics, host immune response intensity, and bacterial superinfection risk. Influenza A subtypes (H1N1, H3N2) typically dominate seasonal epidemics; H3N2 carries higher elderly mortality. Influenza B causes outbreaks in school-age populations and has been declining since the COVID-19 era through indirect transmission interruption. Replication peaks at 24-48 hours post-symptom-onset and declines thereafter — this is the rationale for early antiviral administration. The window of maximum benefit from oseltamivir is the first 48 hours, though benefit persists in hospitalized and high-risk patients beyond this window. Bacterial superinfection (most commonly Streptococcus pneumoniae and Staphylococcus aureus, including MRSA) develops in approximately 1-30% of hospitalized influenza patients depending on age and comorbidities — and is the dominant cause of influenza-attributable mortality in older adults. Empirical antibiotic coverage with consideration of MRSA is indicated for any hospitalized influenza patient with radiographic consolidation, elevated procalcitonin, or rapidly worsening clinical trajectory.
S2. Diagnosis: RT-PCR vs Rapid Antigen vs Multiplex Panels
Diagnostic confirmation is recommended when the result will alter clinical management — antiviral initiation, infection control, treatment of close contacts, or distinguishing influenza from COVID-19 and RSV during co-circulating seasons.
Test Comparison
| Test | Sensitivity | Turnaround | When to Use |
|---|---|---|---|
| RT-PCR (single or multiplex) | 95–100% | 1–8 hours (point-of-care 30–45 min) | All hospitalized patients; outpatient when result alters management; preferred during ILI seasons |
| Multiplex respiratory panel (Flu A/B + RSV + SARS-CoV-2 ± others) | 95–100% | 1–2 hours | ED triage, immunocompromised, severe disease — distinguishes co-circulating viruses |
| Rapid molecular (e.g., ID NOW, cobas Liat) | 85–95% | 15–30 min | Point-of-care; outpatient setting |
| Rapid influenza diagnostic test (RIDT) | 50–70% | 10–15 min | Limited utility — high false-negative rate; do not rule out influenza in symptomatic patients during peak season |
| Viral culture | ~100% | 3–10 days | Reference standard; surveillance only |
| Serology | Retrospective | Days–weeks | Public health; not for acute diagnosis |
Specimen Selection
Nasopharyngeal swab is the standard upper respiratory specimen. Mid-turbinate nasal swab is acceptable and better tolerated. In hospitalized patients with negative nasopharyngeal specimens but high clinical suspicion, lower respiratory specimens — endotracheal aspirate, BAL — should be obtained, as influenza virus can persist in lower airways after upper airway clearance. False-negative RIDT in a patient with classic ILI during peak season should not deter empiric antiviral therapy.
Diagnostic Tip — Co-Infection with SARS-CoV-2
During co-circulation of influenza, SARS-CoV-2, and RSV, multiplex PCR panels are more efficient than sequential single-pathogen testing. Co-infection occurs in 1–4% of hospitalized adults during overlapping seasons and is associated with increased severity, longer ICU stay, and higher mortality. Empirically treat both pathogens in severely ill patients pending confirmation.
S3. Antiviral Therapy
Antiviral therapy reduces symptom duration, hospitalization, and mortality (in high-risk and hospitalized patients). Treatment is most effective within 48 hours of symptom onset but should be given to all hospitalized patients regardless of duration because viral replication continues in lower airways. IDSA 2018 strongly recommends antiviral treatment for hospitalized patients, severe or progressive illness, and outpatients at high risk for complications, regardless of laboratory confirmation timing.
Antiviral Drug Comparison
| Drug | Class | Dose (Adult) | Notes |
|---|---|---|---|
| Oseltamivir (Tamiflu) | Neuraminidase inhibitor | 75 mg PO BID × 5 days | First-line for hospitalized and outpatient; renal dose adjustment (CrCl <60: 30–75 mg daily); GI side effects |
| Baloxavir marboxil (Xofluza) | Polymerase acidic (PA) endonuclease inhibitor | 40 mg PO ×1 (40–80 kg) or 80 mg PO ×1 (≥80 kg) | Single dose; outpatient ambulatory only (limited hospitalized data); resistance mutation PA/I38T emerges in 9–23%; not for severely immunocompromised |
| Zanamivir (Relenza) | Neuraminidase inhibitor | 10 mg (2 inhalations) BID × 5 days | Inhaled; avoid in asthma/COPD (bronchospasm); not for hospitalized with severe disease (cannot deliver) |
| Peramivir (Rapivab) | Neuraminidase inhibitor | 600 mg IV single dose (extended for hospitalized) | Single IV dose for outpatient; useful when oral not tolerated; renal dose adjustment |
| Amantadine / Rimantadine | M2 channel inhibitor | — | NOT RECOMMENDED — >99% of seasonal influenza A is resistant; ineffective against influenza B |
Initiation Timing
| Scenario | Recommendation |
|---|---|
| Hospitalized, any duration of illness | Treat — IDSA strongly recommends regardless of time from onset |
| Outpatient, high-risk, ≤48 hours from onset | Treat — proven benefit in reducing complications |
| Outpatient, high-risk, >48 hours from onset | Consider treatment — observational data suggest benefit even at 48–96 hours |
| Outpatient, low-risk, ≤48 hours | Optional — modest symptom reduction; shared decision-making |
| Outpatient, low-risk, >48 hours | Generally not recommended — diminishing benefit |
| Severe progressive disease | Treat regardless of duration; consider extended/higher dose for critical illness |
Extended-Duration Therapy
Severely ill or immunocompromised patients with persistent viral shedding may benefit from extended courses (10 days or until viral clearance). Some experts use double-dose oseltamivir (150 mg PO BID) in critically ill patients on ECMO or with severe ARDS, though randomized data are mixed (no clear mortality benefit but reasonable for selected cases). Renal dose adjustment is critical at high doses.
Resistance Considerations
| Antiviral | Resistance Mutation | Frequency |
|---|---|---|
| Oseltamivir | NA H275Y (H1N1) | <1% in 2026 surveillance; widespread in 2007–2008 H1N1 |
| Oseltamivir/peramivir | NA R292K, E119V (H3N2) | Rare; usually treatment-emergent in immunocompromised |
| Baloxavir | PA I38T/F/M | 9–23% treatment-emergent in clinical trials |
| Amantadine/rimantadine | M2 S31N | >99% — not recommended |
Adjunctive Therapy — Corticosteroids in Influenza ARDS
Corticosteroids in influenza pneumonia are not routinely recommended. Observational data suggest increased mortality in influenza pneumonia treated with steroids. They may be appropriate when there is a clear concurrent indication (asthma exacerbation, COPD exacerbation, vasodilatory shock) but should not be given empirically for viral ARDS. NSAIDs (especially aspirin in children) are contraindicated due to Reye syndrome risk in children <18 with febrile viral illness.
S4. Hospital Management, Complications, and Bacterial Co-infection
Hospital Admission Criteria
Admission is warranted for influenza patients with:
- Hypoxemia (SpO2 <92% on room air or new oxygen requirement)
- Respiratory rate >24/min, dyspnea at rest, or work of breathing
- Sepsis physiology (lactate >2 mmol/L, qSOFA ≥2)
- Decompensation of underlying chronic disease (heart failure, COPD, cirrhosis)
- Inability to maintain oral intake or tolerate oral medications
- Altered mental status, dehydration, hemodynamic instability
- High-risk patients with progressive symptoms (pregnancy, immunocompromise, age >65 with multiple comorbidities)
Inpatient Management Bundle
| Intervention | Detail |
|---|---|
| Antiviral | Oseltamivir 75 mg PO BID × 5 days; peramivir IV if NPO; consider extended course if immunocompromised |
| Oxygen support | Conventional O2 → high-flow nasal cannula (HFNC) → NIV (caution: aerosol generation) → mechanical ventilation per ARDSnet protocol |
| Empiric antibacterials (if bacterial superinfection suspected) | Ceftriaxone 1–2 g IV daily + vancomycin (AUC-guided) — consider piperacillin-tazobactam if HCAP risk; obtain blood and respiratory cultures before |
| Infection control | Droplet + contact precautions; private room or cohort with same pathogen; N95 for aerosol-generating procedures |
| VTE prophylaxis | Pharmacologic prophylaxis (heparin 5000 units SC q8h or enoxaparin 40 mg SC daily) given hyperinflammation and immobility |
| Cardiac monitoring | Telemetry; troponin if chest pain or HR/BP instability — myocarditis surveillance |
Bacterial Co-infection / Secondary Bacterial Pneumonia
Bacterial superinfection is the leading cause of influenza-related death. The classic biphasic course — initial influenza illness improving, then 4–14 days later acute deterioration with fever spike, leukocytosis, focal consolidation, and elevated procalcitonin — should trigger empiric antibiotic therapy. The dominant pathogens:
| Pathogen | Empiric Coverage | Notes |
|---|---|---|
| Streptococcus pneumoniae | Ceftriaxone 1–2 g IV daily; doxycycline or fluoroquinolone for outpatient | Most common community pathogen post-influenza |
| Staphylococcus aureus (especially MRSA) | Vancomycin (AUC 400–600) or linezolid 600 mg PO/IV BID | Necrotizing pneumonia, cavitation, hemoptysis; high mortality; PVL toxin in severe cases |
| Group A Streptococcus (S. pyogenes) | Penicillin G + clindamycin (toxin suppression) | Severe sepsis, toxic shock; consider IVIG |
| Haemophilus influenzae | Ceftriaxone | COPD/smokers |
| Pseudomonas aeruginosa | Pip-tazo or cefepime + tobramycin | HCAP risk factors, structural lung disease (CF, bronchiectasis) |
Non-Pulmonary Complications
| Complication | Presentation / Workup |
|---|---|
| Myocarditis | Chest pain, troponin elevation, ECG changes, reduced LVEF on echo; cardiac MRI confirms; can progress to fulminant myocarditis |
| Encephalopathy / encephalitis | Altered mental status, seizures; influenza-associated encephalopathy (IAE) more common in children; check CSF (often acellular), MRI, EEG |
| Rhabdomyolysis | Severe myalgia, dark urine, CK >5,000; treat with IV crystalloid |
| Acute kidney injury | Multifactorial: hypovolemia, rhabdo, sepsis, drug toxicity (vanco, NSAIDs) |
| ARDS | PaO2/FiO2 <300; lung-protective ventilation, prone positioning, ECMO referral when severe |
| Reye syndrome | Avoid aspirin/salicylates in children/adolescents with viral illness |
Critical Pitfall — Missing Necrotizing Staphylococcal Pneumonia
Influenza followed by necrotizing pneumonia with rapid cavitation, hemoptysis, and septic shock should raise concern for community-acquired MRSA producing Panton-Valentine leukocidin (PVL) toxin. Empiric coverage with vancomycin OR linezolid (linezolid preferred when toxin-mediated disease suspected — better toxin suppression) is essential. Mortality exceeds 50% if antibiotic initiation is delayed.
S5. Vaccination Strategies and Post-Exposure Prophylaxis
Annual Influenza Vaccine Options
| Vaccine | Type | Eligible Population | Notes |
|---|---|---|---|
| Quadrivalent inactivated (IIV4) | Inactivated, egg-based or cell-based | ≥6 months | Standard; IM injection; 2 doses for unvaccinated children 6 mo–8 y |
| Recombinant (RIV4) — Flublok | Recombinant HA | ≥18 years | Egg-free; higher antigen content; preferred for severe egg allergy |
| High-dose IIV (Fluzone HD) / adjuvanted (Fluad) | Inactivated | ≥65 years (preferential per ACIP 2022) | Higher immunogenicity; preferred over standard IIV for elderly |
| Live attenuated (LAIV4) — FluMist | Live attenuated, intranasal | 2–49 years, healthy non-pregnant | Avoid in immunocompromise, pregnancy, asthma 2–4 y, severe wheeze |
| Cell-based (ccIIV4) — Flucelvax | Inactivated, cell culture | ≥6 months | Egg-free; useful in egg allergy |
Vaccine Composition and Strain Selection
Northern Hemisphere vaccines are reformulated annually based on WHO surveillance data through the Global Influenza Surveillance and Response System (GISRS). Trivalent (3-strain) vaccines historically included two influenza A strains (H1N1, H3N2) and one influenza B; quadrivalent (4-strain) vaccines add a second B lineage. Following the apparent extinction of B/Yamagata lineage during COVID-19 pandemic (no detection since 2020), 2024–25 vaccines are reverting to trivalent in some markets. Vaccine effectiveness varies year to year (10–60%), with H3N2 seasons tending to have lower effectiveness due to egg-adaptation mutations and antigenic drift.
Vaccination Recommendations
- Universal: All persons ≥6 months annually (CDC/ACIP recommendation)
- Timing: Ideally by end of October; protection wanes after 6 months especially in elderly
- Pregnancy: Vaccinate any trimester (IIV only — not LAIV)
- Egg allergy: Any vaccine acceptable regardless of severity per ACIP 2024 (no observation period required)
- Immunocompromised: IIV/RIV preferred (not LAIV); reduced response — household and close contacts should also be vaccinated
- Elderly ≥65: High-dose, adjuvanted, or recombinant vaccines preferred
Post-Exposure Chemoprophylaxis
| Indication | Drug / Dose | Duration |
|---|---|---|
| High-risk household contact, ≤48 h from exposure | Oseltamivir 75 mg PO daily | 7 days |
| Long-term care facility outbreak | Oseltamivir 75 mg PO daily for all residents (regardless of vaccination status) | 14 days minimum, or 7 days after last case |
| Healthcare worker high-risk exposure (unvaccinated, immunocompromised) | Oseltamivir 75 mg PO daily | 7 days |
| Single dose post-exposure (ambulatory, household) | Baloxavir 40–80 mg PO ×1 | Single dose (BLOCKSTONE trial) |
Vaccination is preferred over chemoprophylaxis for sustained protection. Chemoprophylaxis bridges the 2-week interval after vaccination required for protective antibody development, or substitutes when vaccination is contraindicated or unavailable.
Practice Insights: Influenza — Empirical Treatment in High-Risk Groups and MRSA-Aware Superinfection Coverage
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Testing and treating are two separate decisions in influenza, and collapsing them into one is how the treatment window is spent waiting for a result: (1) empirical antiviral treatment is initiated in high-risk groups before test results return — the 48-hour window cannot be wasted; (2) MRSA coverage is added empirically for any hospitalized influenza patient with radiographic consolidation or rapid deterioration; (3) baloxavir marboxil single-dose offers convenience for outpatient high-risk patients but resistance emergence on baloxavir is real and clinicians monitor closely. The "wait for confirmatory PCR" approach during flu season costs the treatment window in patients who need it most.
Empirical oseltamivir for high-risk groups before PCR returns
The IDSA 2018 guidelines emphasize empirical antiviral treatment in high-risk patients (age < 2 or > 65, pregnancy, immunocompromised, chronic respiratory or cardiac disease, BMI > 40) presenting during influenza season — don't wait for confirmatory testing. Rapid antigen sensitivity is only 50-70%; PCR turnaround is hours-to-days depending on platform. clinicians start oseltamivir 75 mg PO BID for 5 days at the bedside in any high-risk patient with clinical signs (fever + myalgia + cough or sore throat). If PCR returns negative experienced clinicians can discontinue; the cost of empirical treatment is minimal compared to the cost of missing the window in a high-risk patient.
Baloxavir single-dose for outpatient adults; oseltamivir for hospitalized
Baloxavir marboxil 40-80 mg PO single dose (FDA 2018) offers convenience and adherence advantages in outpatient adult settings — one dose, done. Seasoned clinicians prescribe baloxavir for healthy outpatient adults who can complete the dose at the clinic. For hospitalized patients they default to oseltamivir 75 mg BID for 5 days (longer treatment course may benefit severe disease per observational data). For severely ill or unable to swallow patients, IV peramivir 600 mg single dose is the alternative. Resistance to baloxavir (PA-I38T mutation) is increasing — emerging surveillance data suggests 5-10% in some regions. clinicians check local resistance patterns before prescribing baloxavir.
MRSA-aware empirical antibiotic coverage for radiographic consolidation
Bacterial superinfection in influenza is dominantly Staphylococcus aureus (often MRSA, particularly post-pandemic) and Streptococcus pneumoniae. For any hospitalized influenza patient with radiographic consolidation, elevated procalcitonin (> 0.5), or rapidly worsening clinical trajectory, clinicians add empirical MRSA-aware coverage: ceftriaxone 1-2 g IV daily PLUS vancomycin 15-20 mg/kg q8-12h (target trough 15-20). For hospital-acquired flu or healthcare-associated risk, experienced practitioners substitute piperacillin-tazobactam 4.5 g IV q6h for pseudomonas coverage. Linezolid 600 mg IV/PO q12h is an alternative to vancomycin in renal dysfunction.
Vaccination optimization: high-dose for elderly, recombinant for egg allergy
Annual influenza vaccination is the single most cost-effective intervention experienced clinicians prescribe. For age ≥ 65, clinicians prefer high-dose (Fluzone HD) or adjuvanted (Fluad) formulations — these have demonstrated better immunogenicity and clinical effectiveness in this age group. For egg allergy, recombinant flu vaccine (Flublok) or cell-based (Flucelvax) avoids egg protein entirely. Pregnancy: inactivated quadrivalent at any trimester is safe and recommended — passive immunity protects newborns through the first 6 months. Live attenuated nasal spray (FluMist) is for healthy ages 2-49 only — avoid in pregnancy, immunocompromised, asthma. Experienced clinicians track unvaccinated patients in clinic and offer at every visit during October-March.
Anonymized Case: COPD + Influenza A with Bacterial Superinfection
A man in his late sixties with severe COPD (FEV1 35%) on home oxygen presented in mid-January with 3 days of fever (38.6°C), myalgia, productive cough, and increased dyspnea. Vital signs: SpO2 88% on 2 L home O2 (baseline 92%), HR 108, RR 24. Initial rapid antigen test: RSV negative. The treating clinicians sent influenza PCR but did not wait for results — started oseltamivir 75 mg PO BID empirically (high-risk: COPD + age > 65). PCR returned 6 hours later: Influenza A positive. Chest X-ray showed right lower lobe consolidation. CRP 145 mg/L, procalcitonin 0.9 ng/mL — concerning for bacterial superinfection. clinicians added ceftriaxone 1 g IV daily plus vancomycin 15 mg/kg IV q12h empirically (MRSA-aware coverage given pandemic-era CA-MRSA rates). Blood cultures grew nothing; sputum culture grew methicillin-sensitive Staphylococcus aureus — vancomycin was discontinued, ceftriaxone narrowed to cefazolin 2 g IV q8h based on susceptibility. Continued oseltamivir for 5 days. He recovered to baseline by day 7 and was discharged on day 8. Vaccination history review: missed influenza vaccine this season due to scheduling. He was vaccinated before discharge and counseled on annual flu vaccination + COPD action plan.
Four Protocol Deviations Seasoned Clinicians Now Default To
- Empirical oseltamivir 75 mg BID x 5 days for any high-risk patient with clinical influenza during flu season — before PCR returns. High-risk: age < 2 or > 65, pregnancy, immunocompromised, chronic respiratory or cardiac disease, BMI > 40. Discontinue if PCR negative; cost of empirical treatment is far less than cost of missing the 48-hour window.
- Baloxavir 40-80 mg single dose for outpatient adults; oseltamivir 75 mg BID x 5 days for hospitalized; peramivir 600 mg IV for unable-to-swallow. Check local baloxavir resistance patterns before prescribing — PA-I38T mutation rates emerging at 5-10% in some regions.
- Empirical MRSA-aware antibiotic coverage (ceftriaxone + vancomycin) for hospitalized influenza patients with radiographic consolidation, procalcitonin > 0.5, or rapid deterioration. Narrow to specific organism once cultures return. Substitute pip-tazo for healthcare-associated risk requiring Pseudomonas coverage. Linezolid alternative to vancomycin in renal dysfunction.
- Influenza vaccination optimization: high-dose or adjuvanted for age ≥ 65; recombinant or cell-based for egg allergy; inactivated for pregnancy (any trimester). Live attenuated (FluMist) for healthy ages 2-49 only — never pregnancy, immunocompromised, asthma. Vaccinate at every contact during October-March; passive immunity in pregnancy protects newborns through first 6 months.
S6. Pearls, Pitfalls, and FAQ
Pearl — Treat Hospitalized Patients Regardless of Time
The 48-hour antiviral window applies to outpatient symptom relief. Hospitalized patients with influenza benefit from oseltamivir even when started 5–7 days into illness because viral replication continues in lower airways and ICU patients often shed virus for prolonged periods. Do not withhold antivirals based on duration in hospitalized patients.
Pitfall — Trusting a Negative Rapid Antigen Test
RIDT sensitivity is 50–70% in adults. A negative rapid test in a patient with classic ILI during peak season does not rule out influenza. Send confirmatory RT-PCR if the result will alter management, or empirically treat high-risk patients while awaiting PCR. False-negative rapid tests cost antiviral windows.
Pearl — Suspect Bacterial Superinfection on Day 5–14
The classic biphasic course of influenza followed by recurrent fever, leukocytosis, focal consolidation, and elevated procalcitonin should trigger empiric antibacterial therapy. Cover S. pneumoniae and S. aureus (including MRSA in the setting of necrotizing pneumonia, hemoptysis, or cavitation). Send blood and respiratory cultures before antibiotics.
Pitfall — Routine Corticosteroids in Influenza ARDS
Observational data suggest that corticosteroids are associated with increased mortality in influenza pneumonia and ARDS. Reserve steroids for clear concurrent indications (asthma exacerbation, COPD exacerbation, septic shock with vasopressor requirement) — do not give empirically for viral ARDS or as adjunctive therapy.
FAQ
IDSA 2018 strongly recommends antivirals for all hospitalized patients with confirmed or suspected influenza (regardless of duration), all patients with severe or progressive illness (including outpatients), and outpatients at high risk for complications (≥65 years, pregnancy, chronic disease, immunocompromise, BMI ≥40, long-term care residents). For low-risk outpatients within 48 hours of symptom onset, antivirals modestly shorten illness and are optional based on shared decision-making.
Oseltamivir 75 mg PO BID × 5 days remains first-line for hospitalized patients and most outpatients due to robust efficacy data, low resistance rates, and use in pregnancy and immunocompromise. Baloxavir 40–80 mg PO single dose is approved for ambulatory outpatients ≥12 years and offers the convenience of single-dose therapy. Treatment-emergent PA/I38T resistance occurs in 9–23% with baloxavir; not recommended for severely immunocompromised patients due to resistance concerns. For hospitalized patients, oseltamivir is preferred.
Suspect bacterial superinfection in influenza patients with new fever after initial improvement, leukocytosis (or marked leukopenia), focal consolidation on chest imaging, hemoptysis or purulent sputum, or elevated procalcitonin (>0.5 ng/mL). Empiric ceftriaxone 1–2 g IV daily plus vancomycin (AUC 400–600) covers the dominant pathogens — S. pneumoniae and S. aureus including MRSA. Linezolid 600 mg PO/IV BID is preferred over vancomycin when toxin-mediated necrotizing pneumonia is suspected. Send blood and respiratory cultures before initiating antibiotics.
Admit for hypoxemia (SpO2 <92% on room air), tachypnea (RR >24) or work of breathing, sepsis physiology (lactate >2 mmol/L, qSOFA ≥2), decompensation of underlying chronic disease (HF, COPD, cirrhosis), inability to take oral therapy, altered mental status, or progression in high-risk patients. Many high-risk patients without these features can be managed as outpatients with oseltamivir and close follow-up.
Yes — CDC/ACIP recommends annual influenza vaccination for all persons ≥6 months without contraindications. Patients ≥65 should preferentially receive high-dose (IIV-HD), adjuvanted (aIIV4), or recombinant (RIV4) vaccines. Pregnant women receive IIV any trimester. Egg allergy is no longer a contraindication to any vaccine per ACIP 2024 (observation period not required). LAIV is contraindicated in immunocompromise, pregnancy, severe asthma, and children <2 years.
Oseltamivir 75 mg PO daily × 7 days is indicated for high-risk household contacts of confirmed cases when initiated within 48 hours of exposure, all residents of long-term care facilities during outbreaks (regardless of vaccination status, ≥14 days or 7 days after last case), and unvaccinated immunocompromised healthcare workers with high-risk exposure. Vaccination is preferred for sustained protection; chemoprophylaxis bridges the 2-week interval to vaccine effectiveness.
Corticosteroids are not routinely recommended in influenza pneumonia or ARDS — observational data suggest increased mortality. Reserve steroids for concurrent indications (asthma/COPD exacerbation, septic shock requiring vasopressors). Aspirin and salicylates are contraindicated in children and adolescents <18 years with viral illness due to Reye syndrome risk; use acetaminophen or ibuprofen for fever and pain control instead.
- Invasive Candidiasis and Candidemia: Diagnosis, Echinocandin Therapy, and Source Control
- Cryptococcal Meningitis: CSF Diagnosis, Induction Antifungal Therapy, and ICP Management
- Invasive Aspergillosis: Galactomannan Diagnosis, Voriconazole and Isavuconazole Therapy
- Active Pulmonary Tuberculosis: Diagnosis, RIPE Therapy, and DOT Strategy
- HIV and AIDS: Diagnosis, Antiretroviral Therapy, and Monitoring
- Pulmonary Tuberculosis: Diagnosis, RIPE Therapy, and Monitoring